LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Macrophage Role in Infection Determined by PI-3 Kinase-Gamma Signaling

By LabMedica International staff writers
Posted on 29 Sep 2016
Image: Researchers have identified a molecule that controls immune suppression, which could enhance molecular abilities to fight disease (Photo courtesy of Pixabay).
Image: Researchers have identified a molecule that controls immune suppression, which could enhance molecular abilities to fight disease (Photo courtesy of Pixabay).
Cancer researchers have identified a molecule responsible for the signal that converts macrophages from an inflammatory, immunostimulatory mode in acute infections to an anti-inflammatory, immunosuppressive mode that supports tumor development and growth.

Macrophages play critical, but opposite, roles in acute and chronic inflammation and cancer. In response to pathogens or injury, inflammatory macrophages express cytokines that stimulate cytotoxic T-cells, while highly abundant macrophages in cancer and parasitic diseases express anti-inflammatory cytokines that induce immune suppression and may promote tumor growth.

Investigators at the University of California, San Diego (USA) reported in the September 19, 2016, online issue of the journal Nature that results of experiments carried out with mouse models had allowed them to identify the macrophage enzyme PI-3 kinase-gamma (PI3K-gamma) as the controller of a critical switch between immune stimulation and suppression during inflammation and cancer.

PI3K-gamma signaling induced a transcriptional program that promoted immune suppression during inflammation and tumor growth. In contrast, selective inactivation of macrophage PI3K-gamma promoted an immunostimulatory transcriptional program that restored CD8+ T-cell activation and cytotoxicity and synergized with checkpoint inhibitor therapy to promote tumor regression and extend survival in mouse models of cancer.

“Immunotherapies, such as T-cell checkpoint inhibitors, are showing great promise in early treatments and trials, but they are not universally effective,” said senior author Dr. Judith A. Varner, professor of pathology and medicine at the University of California, San Diego. “We have identified a new method to boost the effectiveness of current immune therapy. Our findings also improve our understanding of key mechanisms that control cancer immune suppression and could lead to the development of more effective immunotherapies.”

Related Links:
University of California, San Diego

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Gold Member
Collection and Transport System
PurSafe Plus®

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more